HC Wainwright Lowers Rockwell Medical (NASDAQ:RMTI) Price Target to $3.00

Rockwell Medical (NASDAQ:RMTI) had its target price trimmed by HC Wainwright from $7.00 to $3.00 in a research note released on Monday, Marketbeat.com reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Rockwell Medical’s Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.10) EPS, Q1 2026 earnings at ($0.02) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.06) EPS.

Separately, StockNews.com downgraded Rockwell Medical from a “buy” rating to a “hold” rating in a report on Friday, December 20th.

Rockwell Medical Trading Up 3.3 %

NASDAQ RMTI opened at $1.24 on Monday. The company’s fifty day simple moving average is $1.80 and its 200-day simple moving average is $2.57. The stock has a market cap of $40.08 million, a P/E ratio of -24.80 and a beta of 1.55. Rockwell Medical has a 52 week low of $1.18 and a 52 week high of $5.15. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). The firm had revenue of $24.67 million during the quarter, compared to analyst estimates of $23.65 million. Rockwell Medical had a positive return on equity of 8.55% and a negative net margin of 1.25%. Equities research analysts predict that Rockwell Medical will post 0.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. acquired a new stake in shares of Rockwell Medical in the 4th quarter valued at about $28,000. Two Sigma Securities LLC acquired a new stake in Rockwell Medical during the fourth quarter valued at approximately $33,000. Barclays PLC bought a new position in Rockwell Medical during the 3rd quarter worth approximately $90,000. XTX Topco Ltd grew its position in shares of Rockwell Medical by 45.7% in the 3rd quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after acquiring an additional 8,922 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Rockwell Medical by 134,397.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 47,074 shares of the company’s stock valued at $187,000 after acquiring an additional 47,039 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.